Amedisys (AMED)
(Delayed Data from NSDQ)
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Align Technology (ALGN) Prospects Bright, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.
PetMed Express Optimistic on New Orders Amid Stiff Rivalry
by Zacks Equity Research
PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.
Anthem to Boost Medicare in Florida With HealthSun Buyout
by Zacks Equity Research
Anthem's (ANTM) inorganic growth continues to boost its top line. It strategically deploys capital in acquisitions to position its Medicare business for further growth.
Medtronic Advances in Pain Therapy With U.S. Intellis Launch
by Zacks Equity Research
We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
Why Should Investors Add Amedisys (AMED) to Their Portfolio?
by Zacks Equity Research
Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.
Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?
by Zacks Equity Research
Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.
Here's Why You Should Add Chemed (CHE) to Your Portfolio
by Zacks Equity Research
Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.
Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now
by Zacks Equity Research
BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.
Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy
by Zacks Equity Research
The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.
Boston Scientific MultiSENSE Study on HeartLogic Positive
by Zacks Equity Research
Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.
Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.
Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments.
Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5
by Zacks Equity Research
Varian Medical (VAR) is consistently trying to turn around its Oncology Systems business.
Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?
by Zacks Equity Research
Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.
5 MedTech Stocks to Pick for Stellar Returns
by Zacks Equity Research
While the MedTech industry has been grappling with multiple issues, these stocks with high growth potential can be great bets.
Why the Earnings Streak Will Continue for Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.
Inovalon Holdings' ONE Platform Chosen by UnitedHealthcare
by Zacks Equity Research
Inovalon Holding (INOV) will be able to expand in the population health management space through the selection of its proprietary ONE Platform by UnitedHealthcare.
Fresenius Medical Opens Manufacturing Plant in Malaysia
by Zacks Equity Research
Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.
Amedisys Rides High on Strong Prospects Amid Margin Woes
by Zacks Equity Research
Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.
Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
IDEXX Laboratories Rides High on Strong CAG, Global Growth
by Zacks Equity Research
IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.
Medtronic Launches StealthStation Technology, Expands in ENT
by Zacks Equity Research
Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.